Illumina
Illumina develops DNA sequencing and array-based technologies for genomics research and clinical applications, generating over 90% of the world's sequencing data.
External Program
Submit bugs directly to this organization
Illumina
Illumina develops DNA sequencing and array-based technologies for genomics research and clinical applications, generating over 90% of the world's sequencing data.
External Program
Submit bugs directly to this organization
At Illumina, we believe safeguarding sensitive data is foundational to genomic innovation and customers are the heart of everything we do. As part of our ongoing commitment to security, we maintain a dedicated Product Security team responsible for evaluating and implementing security controls, managing cybersecurity risk across our various product lines, and executing our cybersecurity post-market product surveillance and support program.
We recognize and appreciate the value provided by our customers and security researchers in identifying cybersecurity risks on Illumina's products and look forward to collaborating with those partners in good faith.
The scope of the Illumina Coordinated Vulnerability Disclosure Program includes on-market products and associated SaaS applications (e.g. BaseSpace Sequence Hub, Illumina Connected Analytics, Illumina Connected Insights, Correlation Engine, ClarityLIMS, Emedgene).
Infrastructure and software owned and used by Illumina in operating its business are out of scope of this Coordinated Vulnerability Disclosure Program. Additionally, the Coordinated Vulnerability Disclosure Program should not be used for submitting adverse events or product quality complaints. Please follow the appropriate processes laid out by the individual product lines for reporting these types of issues.
If you have identified a potential security vulnerability, please email us at [email protected] to initiate communication.
After communication is established, we may request that you enable email encryption using the details below:
In the initial email, please provide all relevant technical details about the vulnerability, including, but not limited to:
Important: Do not include any Personally Identifiable Information (PII) or Individually Identifiable Health Information (IIHI) in your message.
For any research being conducted on Illumina products, we ask researchers to:
After receiving notice of a potential vulnerability, Illumina will:
If you share any information with Illumina, you agree that the information you submit will be considered as non-proprietary and non-confidential, and that Illumina is allowed to use such information in good faith, in any manner, in whole or in part, and without any restriction.